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Reply to the Editor:
My colleagues and I thank Lange and
colleagues for pointing out that we omit-
ted mentioning the importance of volatile
anesthetics and ischemic preconditioning
(IPC) in a number of animal models and
possibly human beings. For example,
Kersten and coworkers1 showed that
halothane preconditioning in barbiturate-
anesthetized dogs led to a profound in-
farct size reduction (25.3%  2.9% to
11.8%  2.7%) and that this reduction
was as effective as IPC (9.6%  2.0%).
We were remiss in not discussing these
results and their importance to IPC.
Lange and colleagues also stated, “Anes-
thetic preconditioning significantly re-
duces arrhythmias after ischemic peri-
ods.” The antiarrhythmic effect of
volatile anesthetics is more problematic.
Recently Owczuk and associates2 dis-
cussed how desflurane can prolong the
QTc interval and may result in lethal
cardiac arrhythmias. Huneke and co-
workers3 also reported that halothane,
and to a lesser extent isoflurane and
sevoflurane, may lead to ventricular ar-
rhythmias by shortening the refractory
period. In addition, volatile anesthetics
are known to inhibit a number of voltage-
gated potassium ion channels, which
could further increase the risk of ventric-
ular tachycardia in predisposed patients.3
It is unfortunate that most animal studies
investigating volatile anesthetics and IPC
rarely report the incidence and duration
of arrhythmias during ischemia-reperfu-
sion. On the other hand, we reported that
pretreating the heart with an intravenous
solution of the adenosine A1 receptor
agonist 2-chloro-N6-cyclopentyladenosine and
sodium ion fast-channel modulator lidocaine
(A1L) administered 5 minutes before and
during 30 minutes of acute regional ischemia
in the rat in vivo resulted in no deaths, virtu-
ally no severe ventricular arrhythmias and an
infarct size equivalent to that seen with IPC.4
Finally, Lange and colleagues believe it is
unlikely that the administration of a selective
A1 agonist plus a volatile anesthetic could
further enhance cardioprotection. However,
we believe the combination may reduce the
amount of each agent needed to exert cardio-
protection; that is, the A1 receptor agonist
may reduce the effective therapeutic thresh-
old of the volatile anesthetic agent. This con-
cept was recently reported by Chiari and col-
leagues,5 in whose study postconditioning
during early reperfusion reduced the concen-
tration of isoflurane necessary to exert car-
dioprotection. Because the underlying mech-
anisms of volatile anesthetics and the A1L
combination are not fully understood, the
synergistic effects of volatile anesthetics and
A1 analogs (or A1L) remain to be deter-
mined. Moreover, modulating cardiac volt-
age-gated sodium ion fast channels with local
anesthetics has received surprisingly little at-
tention in IPC strategies, despite the resetting
of the resting membrane potential toward a
more depolarized state during ischemic inju-
ry.3 To quote nineteenth century essayist and
politician Benjamin Disraeli, “What we an-
ticipate seldom occurs; what we least ex-
pected generally happens.”5 Importantly, our
work has shown that it is the combination of
A1 agonist (or adenosine) and lidocaine ad-
ministration that confers functional, electri-
cal, and metabolic protection during myocar-
dial ischemia-reperfusion.3 It would be of
interest to study the effects of volatile anes-
thetics in the presence of the combination of
A1 agonist (or adenosine) and lidocaine dur-
ing and after acute myocardial ischemia in
clinically relevant experimental models.6
Geoffrey P. Dobson, MSc, PhD
Department of Physiology and Pharmacology
James Cook University, Townsville,
Queensland, Australia
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Management of pediatric airway
obstruction
To the Editor:
We read with interest Vinograd and col-
leagues’ article1 on the management of
airway obstruction in children by using self-
expandable metal stents (SEMS). We com-
mend the authors on a thorough and detailed
description of the difficulties encountered in
treating children with this complex problem.
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The options available to treat pediatric air-
way obstruction include surgical resection
and anastomosis (including slide tracheo-
plasty), silicone (eg, Dumon) stents, Mont-
gomery T-tubes, and SEMS. Recently, there
has been a disturbing trend of using SEMS
as the first option in treating benign tracheo-
bronchial pathology, primarily because of
the ease of deployment and the dramatic
relief of obstruction in the short term.2 We
feel that it needs to be reiterated strongly
that SEMS should remain the last resort in
patients with benign stenosis or those with
a surgically correctable airway obstruction.
SEMS have a number of complications that
are difficult to treat long-term. The ideal
indication for SEMS is a patient with ter-
minal malignancy with airway obstruction
in whom the expected low survival from
the primary malignancy precludes the oc-
currence of stent-related complications.
SEMS cause intense granulation tissue,
which often causes the same symptoms for
which the stent was deployed; subsequent
attempts to alleviate this problem with la-
ser, electrocautery, and so on usually have
disappointing results. Moreover, contrary
to the authors’ views, removal of these
stents is difficult and fraught with danger.
Single and short-segment tracheal stenosis
should be treated by primary surgery in
centers experienced in pediatric tracheal
surgery. Stenting should be reserved for
patients in an acute situation (where sili-
cone stents may be deployed as a tempo-
rary measure) before referral to a center
specializing in tracheal surgery.
Although not practical in infants and
very small children, Dumon stents and
Montgomery T-tubes are invaluable in
stenting lesions that are too long for safe
reconstruction.3 More often than not, the
stent stabilizes the airway, and decannula-
tion is possible in most cases.4 Moreover,
the ease with which silicon stents can be
removed if definitive surgery is being con-
sidered makes it an attractive option to tide
over an acute situation. The pediatrician,
pulmonologist, or thoracic surgeon in-
volved in managing complex airway prob-
lems needs to be aware of the basic under-
lying pathology and intelligently apply the
right solution to a specific problem.
C. S. Pramesh, MS, FRCS
Rajesh C. Mistry, MS
Division of Thoracic Surgery
Tata Memorial Hospital
Mumbai, India
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Reply to the Editor:
In my article I emphasized that the use of
intratracheal stents in children is dangerous
and carries the risk of severe complications.
With regard to the use of self-expandable
metallic stents (SEMS), I completely agree
that their use should be avoided. There are
enough data in the literature to support
this.1 The SEMS in this study were made
from nitinol, an alloy with a “shape mem-
ory effect.” In animal studies, this stent,
because of its unique biochemical property,
could he fixed and removed easily, even in
very small airways.2 In children, their use
was associated with an excessive granula-
tion, and although the extraction proved to
be easy and smooth, their application is
currently suspended.
Currently available silicone or Dumoan
stents have an external diameter that pre-
vents their use in infants and small chil-
dren.
The Montgomery and I-tubes could be
an option in tracheal strictures, but they are
not practical in bronchial or distal airway
problems.
I would like to thank Mr Pramesh for
his remarks.
Itzhak Vinograd, MD
Department of Pediatric Surgery
DANA Children’s Hospital
Sackler Faculty of Medicine
Tel Aviv University
Tel Aviv, Israel
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Molecular changes occurring with
aneurysm formation: Possible impact
of sampling error
To the Editor:
We congratulate Cotrufo and colleagues1
for exploring messenger RNA expression
and extracellular matrix protein content
in the ascending aorta associated with
bicuspid aortic valves (BAVs), with par-
ticular attention to differences between
the inner and outer curvatures. Our lab-
oratory is also exploring the molecular
changes occurring with aneurysm forma-
tion, and we have been concerned about
the potential impact of sampling error on
experimental results.
Cotrufo and colleagues1 demonstrated dif-
ferences in levels of collagens I, III, and IV, as
well as fibronectin and laminin protein, by
western blot analysis when comparing samples
taken from the concave and convex portions of
dilated aortas resected from patients with BAV.
Additionally, they reported differences between
patients with functionally regurgitant versus ste-
notic valves. Importantly, Cotrufo and col-
leagues1 also reported significant differences in
protein levels between dilated aortas (regardless
of functional valve pathology) and normal con-
trol aortas. Indeed, these differences were as
striking as those observed between concavity
and convexity or between stenotic and regurgi-
tant specimens.
We too are intrigued by the observations
made on aneurysmal tissues, but we urge
caution in interpreting the comparisons made
between dilated aortas and the control group.
A marked difference in age may have pro-
foundly impacted results. Cotrufo and col-
leagues1 reported mean ages for the regurgi-
tation, stenosis, and control groups as 56 9,
59 12, and 33 8 years, respectively. The
95% confidence intervals for these groups
(from data provided in the article’s on-line
Table E11) were 51.2-61.4, 50.9-66.4, and
24.6-41.4 years, respectively. The difference
in collagen expression led Cotrufo and col-
leagues1 conclude that “collagen degradation
by proteinases could prevail over collagen
synthesis” and that smooth muscle cells
“could react differently to different types and
degrees of mechanical stress and could favor,
in turn, a predominant production of either
ECM [extracellular matrix] proteins or pro-
teolytic enzymes.” An alternative hypothesis
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